Mortality surrogates in combined pulmonary fibrosis and emphysema

An Zhao, Eyjólfur Gudmundsson, Nesrin Moğulkoç, Coline van Moorsel, Tamera J. Corte, Pardeep Vasudev, Chiara Romei, Robert Chapman, T Wallis, Emma Denneny, Tinne Goos, Recep Savaş, Asia Ahmed, Christopher J. Brereton, Hendrik W. van Es, Helen E. Jo, Annalisa De Liperi, Mark Duncan, Katarina Pontoppidan, Laurens De Sadeleer, Frouke van Beek, Joseph Barnett, Gary Cross, Alex Procter, Marcel Veltkamp, Peter Hopkins, Yuben Moodley, Alessandro Taliani, Magali N. Taylor, Stijn E. Verleden, Laura Tavanti, Marie Vermant, Arjun Nair, Iain Stewart, Sam M. Janes, Alexandra L. Young, David Barber, Daniel C. Alexander, Joanna C. Porter, Athol U. Wells, Mark G. Jones, Wim Wuyts, Joseph JacobEuropean 2023 · DOI

Introduction

In the clinical management of Idiopathic Pulmonary Fibrosis (IPF), monitoring disease progression is vital for determining prognosis and the timing of therapeutic interventions. Historically, Forced Vital Capacity (FVC) has served as the "gold standard" surrogate for mortality and the primary endpoint in nearly all major clinical trials. However, a significant subset of patients presents with Combined Pulmonary Fibrosis and Emphysema (CPFE), a condition where scarring in the lower lungs co-exists with airway destruction in the upper lungs.

Research published in the European Respiratory Journal suggests that for these patients, FVC is a deceptive metric. The study demonstrates that when emphysema is present, diffusing capacity ($D_{LCO}$) provides a far more accurate signal of mortality risk, necessitating a shift in how clinicians monitor disease progression.

The Mechanical Paradox of CPFE

The primary challenge in monitoring CPFE is a phenomenon known as "mechanical cancellation." Fibrosis causes the lungs to become stiff and contracted, which reduces lung volume and lowers FVC. Conversely, emphysema leads to air-trapping and hyperinflation, which increases lung volumes.

In a patient with both conditions, these opposing forces can mask one another. A patient’s health may be deteriorating significantly due to advancing fibrosis, but their FVC may appear stable because the concurrent emphysema prevents the expected volume loss. This study sought to identify the specific threshold at which emphysema renders FVC unreliable and to determine which functional metric should replace it.

Study Methodology

The researchers conducted a comprehensive analysis using two large, independent "real-world" cohorts:

  1. Derivation Cohort ($n=500$): Patients from Turkey, the Netherlands, and Italy.
  2. Replication Cohort ($n=510$): Patients from the UK, Belgium, and Australia.

Unlike many clinical trials that exclude patients with significant emphysema, these cohorts represent a broad spectrum of IPF patients. The team employed several technical approaches to analyze the data:

  • Visual CT Scoring: Expert radiologists quantified the extent of fibrosis and emphysema across six lung lobes.
  • Linear Mixed-Effects (LME) Models: These were used to model 1-year trajectories of FVC and $D_{LCO}$ decline while accounting for baseline characteristics.
  • Machine Learning (SuStaIn): The Subtype and Stage Inference algorithm identified data-driven CPFE subtypes based on the spatial progression of 12 imaging biomarkers.
  • Cox Regression: Multivariable models calculated Hazard Ratios (HR) for mortality associated with functional declines.

Key Insights: The 10% Threshold and the Role of $D_{LCO}$

The study identified 10% emphysema on CT as the critical tipping point. Once emphysema exceeds this threshold, the association between FVC decline and mortality weakens significantly. In the replication cohort, FVC decline actually failed to reach statistical significance as a mortality predictor ($p=0.13$) for patients above this threshold.

In contrast, $D_{LCO}$—which measures how effectively oxygen moves from the lungs into the bloodstream—emerged as the "true north" for CPFE patients. Because $D_{LCO}$ is impaired by both fibrosis and emphysema, it does not suffer from the mechanical masking effect seen in FVC. In patients with $\ge10\%$ emphysema, 1-year relative $D_{LCO}$ decline showed a robust association with mortality (HR $\approx$ 1.03–1.04).

Furthermore, the SuStaIn machine learning model identified a "matched" subtype where fibrosis and emphysema progress in tandem. In this specific group, FVC was particularly poor at predicting mortality, reinforcing the need for individualized monitoring based on imaging phenotypes.

Redefining Progression for non-CPFE IPF

The research also carries implications for patients without significant emphysema. Currently, many clinical trials use a 10% relative decline in FVC as the threshold for "progression." However, this study found that in non-CPFE patients, even a 5% relative decline in FVC over one year was a potent indicator of mortality (HR = 3.82 in the derivation cohort; HR = 2.72 in the replication cohort). This suggests that the current 10% threshold may be too conservative, potentially delaying the recognition of disease progression in patients with pure fibrosis.

Limitations and Future Directions

While the findings are compelling, the study acknowledges certain limitations. The reliance on visual CT scoring is subjective and time-consuming, which may limit its immediate scalability in high-volume clinical settings. The authors suggest that fully automated, AI-based quantification of emphysema versus honeycombing is a necessary next step.

Additionally, while the SuStaIn machine learning model provided deep insights into disease subtypes, it remains a research tool that requires further refinement before it can be integrated into standard clinical workflows. Finally, as a retrospective study, the potential for bias due to missing longitudinal data was addressed using LME models, but prospective validation remains ideal.

Conclusion

This research highlights a critical need to personalize the monitoring of IPF based on the presence of emphysema. For patients with $\ge10\%$ emphysema, clinicians should prioritize $D_{LCO}$ decline over FVC to assess mortality risk. For those without emphysema, a more sensitive 5% FVC decline threshold should be considered to capture disease progression earlier. By moving beyond a "one-size-fits-all" approach to lung function, providers can more accurately track the trajectory of these complex respiratory conditions.

Summary updated

Abstract

When assessing disease progression in IPF, <i>D</i> <sub>LCO</sub> decline should be considered in patients with ≥10% emphysema and a ≥5% 1-year relative FVC decline threshold considered in non-CPFE IPF patients.
BibTeX
@inproceedings{zhao2023mortality,
  author = {An Zhao and Eyjólfur Gudmundsson and Nesrin Moğulkoç and Coline van Moorsel and Tamera J. Corte and Pardeep Vasudev and Chiara Romei and Robert Chapman and T Wallis and Emma Denneny and Tinne Goos and Recep Savaş and Asia Ahmed and Christopher J. Brereton and Hendrik W. van Es and Helen E. Jo and Annalisa De Liperi and Mark Duncan and Katarina Pontoppidan and Laurens De Sadeleer and Frouke van Beek and Joseph Barnett and Gary Cross and Alex Procter and Marcel Veltkamp and Peter Hopkins and Yuben Moodley and Alessandro Taliani and Magali N. Taylor and Stijn E. Verleden and Laura Tavanti and Marie Vermant and Arjun Nair and Iain Stewart and Sam M. Janes and Alexandra L. Young and David Barber and Daniel C. Alexander and Joanna C. Porter and Athol U. Wells and Mark G. Jones and Wim Wuyts and Joseph Jacob},
  title = {{Mortality surrogates in combined pulmonary fibrosis and emphysema}},
  booktitle = {European},
  year = {2023},
  doi = {10.1183/13993003.00127-2023},
}
Figure